Abbott Laboratories (ABT) stock

ABTNYSEPharmaceutical PreparationsFiscal year ends December 31

Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 4, 2026Score 12/3049% above fair value

$108.52+1.27 (+1.18%)

Close on Nov 13, 2026Market cap $187.78BP/E 40.2Yield 2.21%

Abbott Laboratories EV/EBITDA

EV/EBITDA is enterprise value divided by EBITDA over the trailing twelve months.

Abbott Laboratories's EV/EBITDA was 29.7× on Nov 11, 2026, against 29.9× a year earlier. Over the last 5 years it ranged from 17.6× to 36.3×, with a median of 29.2×.

EV/EBITDA at the end of each year

Period	Period end	Value	Change (pts)
2026	Nov 11, 2026	29.7×	+0.6
2025	Dec 31, 2025	29.1×	−1.5
2024	Dec 31, 2024	30.7×	−2.9
2023	Dec 29, 2023	33.6×	+12.2
2022	Dec 30, 2022	21.3×	−9.5
2021	Dec 31, 2021	30.8×	−17.7
2020	Dec 31, 2020	48.5×	+9.2
2019	Dec 31, 2019	39.3×	−6.6
2018	Dec 31, 2018	45.9×	−18.1
2017	Dec 29, 2017	64.0×	+44.0
2016	Dec 30, 2016	20.0×	−4.3
2015	Dec 31, 2015	24.4×	−6.0
2014	Dec 31, 2014	30.3×	−5.3
2013	Dec 31, 2013	35.7×	−97.7
2012	Jul 31, 2012	133.4×	+115.8
2011	Dec 30, 2011	17.6×	+3.0
2010	Dec 31, 2010	14.6×	−0.3
2009	Dec 31, 2009	14.9×	–

Where these numbers come from

Parsed from the XBRL in Abbott Laboratories's annual and quarterly filings with the SEC
Per-share figures adjusted for the 2-for-1 split on Jun 1, 1998
Fourth quarters derived from the annual report minus nine months
Every figure in the statements links to its source filing